Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
June 07 2022 - 8:00AM
Business Wire
Demonstrates increasing company commitment to responsible value
creation
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the
“Company”) today announced the release of its second annual (2021)
Corporate Responsibility Report. The report showcases the Company’s
continued progress in deepening its commitment to environmental,
social, and governance (ESG) integration across Amneal strategy,
culture and operations. Updates on actions the Company has taken in
key ESG areas are highlighted alongside the social impacts of our
business as well as the latest information on our diversity data,
employee development and well-being offerings, environmental
programs and responsibility plans for 2022.
“2021 was a year of continued evolution at Amneal. Our employees
delivered a year of strong execution, including a robust cadence of
new product innovations, enhanced operating efficiencies, and
strategic M&A bolstering our core capabilities, pipeline, and
portfolio. At the same time, we made meaningful progress in
elevating our commitment to ESG and more deeply integrating
responsibility within our business strategy, culture and
operations,” said Chirag and Chintu Patel, Co-Chief Executive
Officers.
In 2021, Amneal advanced key ESG efforts by:
- Formalizing the Company’s commitment to environmental, social
and governance (ESG) practices by establishing a dedicated function
and robust foundation to guide ESG programs, data collection and
reporting;
- Strengthening the Company’s commitment to the health,
well-being, and advancement of our diverse employee family through
substantial investments in programs and offerings;
- Elevating the Company’s contributions to strengthening access
and affordability for essential medicines via a deepened product
portfolio of complex generics, biosimilars and innovative Specialty
products;
- Taking meaningful steps to help drive health equity for more
patients around the world by extending business into key
international markets;
- Minimizing consumption of natural resources by driving
efficiencies and investments in key areas across the business;
and
- Enhancing support for communities through partnerships with
therapeutic organizations, philanthropic support and regional/local
employee volunteerism.
Each year, Amneal will strengthen its commitment to ESG,
including updating its reporting to incorporate guidance from key
ESG standard-setting and framework organizations in future
publications. The Company looks forward to providing these and
other ESG updates for key stakeholders as appropriate.
To view Amneal’s Corporate Responsibility report, please visit:
https://www.amneal.com/about/responsibility/
About Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX),
headquartered in Bridgewater, NJ, is a fully integrated essential
medicines company. We make healthy possible through the
development, manufacturing, and distribution of generic and
specialty pharmaceuticals, primarily within the United States. The
Company has a diverse portfolio of over 250 products in its
Generics segment and is expanding across a broad range of complex
products and therapeutic areas, including injectables and
biosimilars. In its Specialty segment, Amneal has a growing
portfolio of branded pharmaceutical products focused primarily on
central nervous system and endocrine disorders, with a pipeline
focused on unmet needs. Through its AvKARE segment, the Company is
a distributor of pharmaceuticals and other products for the U.S.
federal government, retail, and institutional markets. For more,
please visit www.amneal.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220607005339/en/
ESG Emily Parlapiano Director, ESG Programs and Reporting
emily.parlapiano@amneal.com Investors Anthony DiMeo Head of
Investor Relations anthony.dimeo@amneal.com
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024